117 related articles for article (PubMed ID: 8881951)
1. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia.
Matzkin H; Barak M; Braf Z
Br J Urol; 1996 Sep; 78(3):405-8. PubMed ID: 8881951
[TBL] [Abstract][Full Text] [Related]
2. Changes in molecular forms of prostate-specific antigen during treatment with finasteride.
España F; Martínez M; Royo M; Estellés A; Alapont JM; Navarro S; Aznar J; Jiménez-Cruz JF
BJU Int; 2002 Nov; 90(7):672-7. PubMed ID: 12410745
[TBL] [Abstract][Full Text] [Related]
3. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
[TBL] [Abstract][Full Text] [Related]
5. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
6. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
7. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
8. Effects of finasteride on prostate volume and prostate-specific antigen.
Chiu KY; Yong CR
J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071
[TBL] [Abstract][Full Text] [Related]
9. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of men on finasteride.
Gormley GJ
Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
[TBL] [Abstract][Full Text] [Related]
11. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
[TBL] [Abstract][Full Text] [Related]
12. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
13. [PSA values before and after finasteride treatment in patients with benign prostatic hypertrophy].
Trinchieri A; Dell'Orto P
Arch Ital Urol Androl; 1995 Feb; 67(1):33-5. PubMed ID: 7538385
[TBL] [Abstract][Full Text] [Related]
14. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
15. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
16. Drug treatment for benign prostatic hyperplasia. To interpret PSA concentrations in patients taking finasteride, multiply them by two.
Taneja S
BMJ; 1997 Aug; 315(7104):371. PubMed ID: 9270475
[No Abstract] [Full Text] [Related]
17. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
18. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
19. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]